🫁 Lung/Head and Neck — 2026-W41

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Narrative review in Lancet Oncology synthesizing evidence linking the gut microbiome to outcomes with immune checkpoint inhibitors in melanoma, NSCLC, and renal cell carcinoma, and surveying emerging microbiome-directed interventions. Highlights how antibiotic/PPI use and microbial diversity may influence ICI efficacy, informing clinicians on an evolving but still investigational modifiable factor in immunotherapy outcomes.

Randomized phase 2 trial of toripalimab consolidation versus observation after chemoradiotherapy in limited-stage SCLC, published in J Immunother Cancer. Suggests consolidation immunotherapy may improve progression-free survival in this setting, though early termination limits conclusions.

Large retrospective cohort study using the Flatiron database examining timing of next-generation sequencing relative to first-line therapy in advanced NSCLC, published in JCO Precision Oncology. Finds up-front NGS testing is associated with greater use of targeted therapy and longer overall survival, reinforcing guideline recommendations for pre-treatment comprehensive genomic testing.

Single-arm phase 2a trial of an intratumoral oncolytic adenoviral immunotherapy plus valacyclovir in immune checkpoint inhibitor-refractory NSCLC, published in Journal for ImmunoTherapy of Cancer. Shows modest response rates with a subset of long-term survivors, offering an early but not yet practice-changing option for this difficult-to-treat population.

Retrospective SEER-Medicare cohort study in JAMA Network Open comparing palliative care, systemic therapy, and hospice utilization between Medicare Advantage and Traditional Medicare patients with advanced breast, colorectal, lung, pancreatic, or prostate cancer. Highlights insurance-network-related disparities in supportive care access that could inform practice organization, though it does not change treatment selection directly.

Meta-analysis pooling single-arm trials of HER2 TKIs and antibody-drug conjugates in advanced HER2-mutant NSCLC, published in Journal of Thoracic Oncology. Provides comparative efficacy/safety data across mutation subtypes and treatment sequencing to help guide choice between HER2-directed agents absent head-to-head trials.

Systematic review and meta-analysis pooling multiple studies of antibody-drug conjugates in NSCLC patients with and without brain metastases, published in Lung Cancer (Q2). Supports that ADCs retain meaningful systemic and intracranial activity in this underrepresented population, informing treatment choice for patients with brain metastases.

Trial design/protocol paper in Future Oncology describing the randomized phase II/III STELLAR-311 study comparing zanzalintinib to everolimus in advanced neuroendocrine tumors (pancreatic and extra-pancreatic, including lung). No efficacy results are reported yet, so it informs awareness of an ongoing trial rather than changing current practice.

Population-cohort genomic analysis (UK Biobank, All of Us) published in Journal of Thoracic Oncology linking ASXL1-mutant clonal hematopoiesis to increased lung cancer risk, particularly in smokers. Informs understanding of lung cancer risk biology but does not guide treatment selection or patient management directly.

International retrospective cohort study in NSCLC/SCLC patients with prior allogeneic stem cell transplant, published in Lung Cancer, assessing outcomes and safety of immune checkpoint inhibitors in this unique population. Suggests ICIs may be feasible with survival benefit in select post-transplant patients, with low observed GvHD flare risk, informing cautious use in this challenging subgroup.

Retrospective propensity-matched real-world cohort study using TriNetX data in extensive-stage small cell lung cancer patients treated with the bispecific T-cell engager tarlatamab, published in Lung Cancer. Finds several commonly co-prescribed medications (antibiotics, opioids, steroids, etc.) associated with worse survival, suggesting caution in concomitant medication use alongside BiTE therapy.

Small retrospective real-world analysis in Lung Cancer using the MSK-CHORD dataset comparing erlotinib versus osimertinib in rare EGFR L858R+T790M compound-mutant NSCLC. Suggests a potential differential drug-sensitivity signal in this uncommon genotype, informing but not yet changing treatment selection.

Exploratory translational study in advanced NSCLC treated with pembrolizumab, published in Lung Cancer. Serum extracellular vesicle protein signatures were explored as predictors of primary resistance and durable benefit, but remain hypothesis-generating.

Prospective registry-based real-world analysis of second-line therapy in extensive-stage SCLC, published in Lung Cancer. Describes heterogeneous second-line regimens and poor outcomes, underscoring the unmet need but not changing practice.

Multicenter retrospective biomarker study in unresectable locally advanced NSCLC, published in JCO Precision Oncology, developing and validating a PET-CT spatiotemporal heterogeneity model for treatment response and prognosis. Promising prediction tool, but it does not yet inform a specific therapy choice.

Retrospective nationwide real-world cohort of ERBB2-mutant NSCLC, published in European Journal of Cancer. Characterizes variant subtypes and outcomes including trastuzumab deruxtecan use, informing how noncanonical variants may behave and be treated.

Narrative review of pathology advances in thoracic malignancies over 20 years, published in the Journal of Thoracic Oncology. Provides background on classification, biomarker testing and post-neoadjuvant assessment that informs patient stratification.